Technical Analysis for AYTU - Aytu BioScience, Inc.

Grade Last Price % Change Price Change
grade D 1.21 -1.63% -0.02
AYTU closed down 1.63 percent on Friday, October 19, 2018, on 70 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Nov 8

14 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical AYTU trend table...

Date Alert Name Type % Chg
Oct 19 Narrow Range Bar Range Contraction 0.00%
Oct 19 Wide Bands Range Expansion 0.00%
Oct 19 Oversold Stochastic Weakness 0.00%
Oct 18 MACD Bullish Signal Line Cross Bullish -1.63%
Oct 18 Narrow Range Bar Range Contraction -1.63%
Oct 18 Wide Bands Range Expansion -1.63%
Oct 18 Oversold Stochastic Weakness -1.63%
Oct 17 Narrow Range Bar Range Contraction -1.63%
Oct 17 Wide Bands Range Expansion -1.63%
Oct 17 Up 3 Days in a Row Strength -1.63%

Older signals for AYTU ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Is AYTU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 11 These 16 public Colorado companies are concerned about tariffs, according to recent SEC filings
Oct 11 Aytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS(R) for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization
Oct 10 Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Oct 10 The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares
Oct 9 The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
Oct 5 Mid-Afternoon Market Update: SMART Global Jumps Following Strong Q4 Results; Aytu BioScience Shares Slide
Oct 5 Midday Gainers / Losers (10/05/2018)
Oct 5 Mid-Day Market Update: Dow Falls Over 200 Points; KemPharm Shares Plunge
Oct 5 Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/05/2018)
Oct 5 Aytu Bio down 33% ahead of equity offering
See more AYTU news...
Indicators
Indicator Value
52 Week High 123.0
52 Week Low 1.01
Average Volume 323,008
200-Day Moving Average 13.9982
50-Day Moving Average 3.053
20-Day Moving Average 1.789
10-Day Moving Average 1.177
Average True Range 0.3308
ADX 14.52
+DI 28.9222
-DI 26.5283
Chandelier Exit (Long, 3 ATRs ) 3.8076
Chandelier Exit (Short, 3 ATRs ) 2.0024
Upper Bollinger Band 3.1511
Lower Bollinger Band 0.4269
Percent B (%b) 0.29
BandWidth 152.275014
MACD Line -0.5945
MACD Signal Line -0.6303
MACD Histogram 0.0358
Fundamentals Value
Market Cap 4.87 Million
Num Shares 4.02 Million
EPS -48.30
Price-to-Earnings (P/E) Ratio -0.03
Price-to-Sales 4.58
Price-to-Book 0.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.36
Resistance 3 (R3) 1.36 1.32 1.34
Resistance 2 (R2) 1.32 1.28 1.32 1.33
Resistance 1 (R1) 1.26 1.25 1.24 1.26 1.32
Pivot Point 1.22 1.22 1.21 1.22 1.22
Support 1 (S1) 1.16 1.18 1.14 1.16 1.10
Support 2 (S2) 1.12 1.15 1.12 1.09
Support 3 (S3) 1.06 1.12 1.09
Support 4 (S4) 1.06